Navigation Links
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
Date:7/15/2010

- Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial.

- In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's patients in order to progress with the clinical development of this novel compound.

MADRID, July 15 /PRNewswire/ -- Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

Dr. Teodoro del Ser, Director of Clinical Development at Noscira, gave an oral session in the "Therapeutic Strategies" symposium in which he reported that treatment with Nypta(R) (Tideglusib) for 20 weeks was tolerated and had a positive impact on patients' cognitive performance. In order for these results to be statistically significant, they must be confirmed in a Phase IIb trial in which a larger group of patients will be treated for one year.

The Phase IIa trial, which was conducted at three centers in Germany based on advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta(R) (Tideglusib) on a group of Alzheimer's patients. The trial was designed with the primary goal of assessing the safety and tolerability of Nypta(R) (Tideglusib) on these patients.

The
'/>"/>

SOURCE Group Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... Hartford, CT (PRWEB) October 25, 2014 Background: ... for Addiction Recovery (CCAR). He is a pioneer in the ... 30-year career in Connecticut's state treatment system and when he ... had nagged him while in public service. ... are making critical decisions concerning them? , 2. Can ...
(Date:10/25/2014)... October 25, 2014 Market ... Diagnostics Industry, 2009-2019 is a professional and ... Molecular Diagnostics industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Molecular Diagnostics listing their product ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific ... U.S. District Court, Southern District of West Virginia ... on Punitive Damages in a group of cases ... ruling issued on October 21st, U.S. District Judge ...
(Date:10/25/2014)... supply to an arm or a leg before heart surgery ... to a new study. "During heart surgery we ... be able to operate on it. After some time without ... energy because it doesn,t get oxygen. When we shut off ... arm or a leg, the body prepares for an upcoming ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2
... case which took Spain by storm for 2 years, has ... been convicted to around 2000 years in prison for knowingly ... doctor worked in the Valencia area of Spain during 1988 to ... C. ,Maeso who carries the virus too , ...
... of chemo patients, scientists at the Georgia Institute of Technology ... , p53, thought to be essential in helping chemotherapy kill ... researchers found that 70 percent of subjects whose tumors had ... years. Patients with normal p53 displayed only a 30 percent ...
... Technology has revealed that airborne viruses can spread far and ... International Laboratory for Air Quality and Health, said the study ... a metre in the air. ,Professor Morawska ... way droplets carrying viruses are dispersed in the air when ...
... has found that women are significantly less likely than ... levels . ,Elevated LDL cholesterol is an ... single cause of death for both women and men. ... Care for Cardiovascular Disease: Using National Managed Care Performance ...
... may be a biological indicator of the trauma that ... by peers. ,The researchers believe that ... intervention of long-term psychological effects on youth. ... observed by teachers,' said JoLynn V. Carney, Associate Professor ...
... of small breast cancer may be a safe procedure ... according to a recent case report by radiologists at ... presents a case of an 85-year-old woman with two ... therapy, chemotherapy or chemoprevention therapy, says Gale A. Sisney, ...
Cached Medicine News:Health News:Killer Anesthetist Sentenced To 1933 Years In Prison 2Health News:Gene Thought to Help Kill Cancer Cells may Actually Help Them Thrive 2Health News:Out of Reach may Not Always Save You from Catching Cold 2Health News:Women Less Likely to Control LDL Cholesterol Levels Than Men 2Health News:Saliva Helps to Identify Child Victims of Chronic Bullying 2
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Tube with stylet inside. Sterile, Latex ... Rusch endotracheal tube with a preloaded ... saving you time and storage space. ... easy identification and has a stopper ...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
... Rusch Safety Clear Plus™ Cuffed Endotracheal Tube w. ... inside. Sterile, Single use. A quality Rusch endotracheal ... to use saving you time and storage space. ... facilitate smooth withdrawal. It is designed with a ...
Medicine Products: